Other languages Simcere Pharmaceutical Group Limited

Equities

2096

HK0000658531

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 EDT			5-day change	1st Jan Change
5.3 ^HKD	+1.15%		+2.91%	-21.25%

04-25	Simcere Pharmaceutical’ Profit Down 23% in 2023	MT
04-10	Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Simcere Pharmaceutical’ Profit Down 23% in 2023	04-25
Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA	04-09
Simcere Pharmaceutical Group Limited Announces SIM0500 for Injection (a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody) Receives Fast Track Designation by the U.S. Food and Drug Administration	04-09
Simcere Pharmaceutical's 2023 Profit Falls, Misses Estimates; Shares Rise 3%	03-20
Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024	03-20
Simcere Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-20
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China	03-15
Simcere Pharmaceutical Group's Cancer Drug Gets China Nod for Clinical Trials	03-13
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration	03-12
Simcere Pharmaceutical Group's New Anti-Cancer Drug Gets Clinical Trials Approval from the FDA	03-10
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500	03-10
Simcere Pharmaceutical Group Limited Announces Findings of A Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in Jama	02-20
Simcere Pharma's Ischemic Stroke Treatment Results Published in US Neurology Journal	02-20
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023	02-19
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%	02-19
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	02-18
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19	01-18
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets	01-12
Simcere Pharmaceutical Group Limited Announces the Phase III Clinical Study of Suvemcitug for Injection in the Treatment of Platinum-Resistant Ovarian Cancer Has Successfully Met the Primary Study Endpoint	01-03
Simcere Pharmaceutical Unit to Buy Production Facility in Jiangsu Province for 42 Million Yuan	01-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Simcere Pharmaceutical Group Limited

Equities

2096

HK0000658531

Other languages

Filters